阿普米司特抑制炎症性破骨细胞生成
本研究探讨阿普米司特(APR)对破骨细胞生成的影响。APR可抑制活化PBMCs产生破骨细胞生成性细胞因子,并剂量依赖性抑制活化PBMC驱动的破骨细胞分化及PsA和pre-PsA患者PBMCs的体外破骨细胞分化,但对银屑病患者和健康对照无此作用。APR还抑制TNF和IL-17A增强的PsA患者CD14+单核细胞破骨细胞生成和骨吸收活性。
要点
- APR抑制活化PBMCs中关键破骨细胞生成性细胞因子的表达
- APR选择性抑制PsA和pre-PsA患者体外破骨细胞分化,对银屑病患者和健康对照无效
- APR抑制TNF和IL-17A增强的PsA患者单核细胞破骨细胞生成和骨吸收活性
核心结论
- APR不仅抑制破骨细胞生成性细胞因子产生,还直接抑制炎症驱动的破骨细胞生成,提示APR在PsA中具有直接骨保护潜力。
研究设计与样本
- 体外研究:检测APR对活化人PBMCs产生破骨细胞生成性细胞因子的影响,并在活化PBMCs与CD14+单核细胞共培养及TNF/IL-17A刺激单核细胞体系中测试APR对破骨细胞分化的作用。
- 比较PsA、pre-PsA、银屑病患者及健康对照的体外破骨细胞分化,并在OsteoAssay板上测量骨吸收。
主要发现
- APR显著损害活化PBMCs中关键破骨细胞生成性细胞因子的表达。
- APR剂量依赖性地显著抑制活化PBMC驱动的破骨细胞分化以及PsA和pre-PsA患者PBMCs的体外破骨细胞分化,但对银屑病患者或健康对照无显著抑制。
- APR显著抑制TNF和IL-17A增强的PsA患者CD14+血单核细胞的破骨细胞生成和骨溶解活性。
- APR抑制关键破骨细胞融合蛋白DC-STAMP的表达。
临床怎么用
- APR可能通过直接抑制炎症性破骨细胞生成,为PsA患者提供骨保护益处。
- APR对破骨细胞生成的抑制作用在PsA和pre-PsA阶段明显,但在银屑病患者和健康对照中不明显。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Psoriatic arthritis (PsA) is associated with bone erosion and inflammation-induced bone loss, which are mediated by osteoclasts (OC) and modulated by inflammatory cytokines. Apremilast (APR) (a selective phosphodiesterase 4 inhibitor) is efficacious in PsA and acts by inhibiting cytokine production. However, there are no direct data informing whether and how APR affects osteoclast formation in humans. METHODS: Osteoclastogenic cytokine production by activated human peripheral blood mononuclear cells (PBMCs) was measured in the presence and absence of APR. Effects of APR on osteoclast differentiation were tested (i) in co-cultures of activated PBMCs and human CD14+ blood monocytes as well as (ii) in CD14+ blood monocytes stimulated with activated-PBMCs supernatant, TNF or IL-17A. Bone resorption was measured on OsteoAssay plates. Effects of APR on ex vivo osteoclast differentiation were compared in PsA, pre-PsA and psoriasis patients, as well as in healthy controls. RESULTS: APR significantly impaired the expression of key osteoclastogenic cytokines in activated PBMCs. Furthermore, APR dose-dependently and significantly inhibited activated PBMC-driven osteoclast differentiation and ex vivo osteoclast differentiation of PBMCs derived from PsA and pre-PsA patients, but not from psoriasis patients or healthy controls. TNF and IL-17A-enhanced osteoclastogenesis and osteolytic activity of CD14+ blood monocytes from PsA patients was also significantly inhibited by APR. Finally, APR inhibited expression of the key osteoclast fusion protein dendritic cell-specific transmembrane protein. CONCLUSION: Phosphodiesterase 4 targeting by APR not only inhibits osteoclastogenic cytokine production, but also directly suppresses inflammation-driven osteoclastogenesis. These data provide initial evidence that APR has the potential to provide a direct bone protective effect in PsA.
引用
- Degboé Y, Sunzini F, Sood S, et al. Apremilast inhibits inflammatory osteoclastogenesis. Rheumatology (Oxford). 2021. PMID: 33788924. doi:10.1093/rheumatology/keab315
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。